SI
OKUR

Sofinnova Investments’s OnKure Therapeutics OKUR Stock Holding History

Sofinnova Investments’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$587K Buy
+141,700
New +$437K 0.02% 70

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sofinnova Investments's OKUR Position: Q1 2026 in Review

Sofinnova Investments opened a new position in OnKure Therapeutics (OKUR) in Q1 2026: 141,700 shares worth $587K. The stake represents 0.02% of the portfolio and ranks #70 among its holdings.

51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Sofinnova Investments held 141,700 shares of OnKure Therapeutics worth $587K as of Q1 2026.
  • OnKure Therapeutics was a new Sofinnova Investments position in Q1 2026.
  • OnKure Therapeutics made up 0.02% of Sofinnova Investments's portfolio in Q1 2026, its #70 holding.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.